Abstract
BackgroundOutcomes data regarding advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective series and post hoc analyses of clinical trials.MethodsIn this multi‐center retrospective study, data were abstracted from the medical records of 350 patients from nine sarcoma centers throughout the United States and combined into a registry. Patients with advanced/unresectable or metastatic SS (n = 249) or MRCL (n = 101) who received first‐line systemic anticancer therapy and had records of tumor imaging were included. Overall survival (OS), time to next treatment, time to distant metastasis, and progression‐free survival (PFS) were evaluated using the Kaplan‐Meier method and Cox regression.ResultsAt start of first‐line systemic anticancer therapy, 92.4% of patients with SS and 91.1% of patients with MRCL had metastatic lesions. However, 74.7% of patients with SS and 72.3% of patients with MRCL had ≥2 lines of systemic therapy. Median OS and median PFS from first‐line therapy for SS was 24.7 months (95% CI, 20.9‐29.4) and 7.5 months, respectively (95% CI, 6.4‐8.4). Median OS and median PFS from start of first‐line therapy for MRCL was 29.9 months (95% CI, 27‐44.6) and 8.9 months (95% CI 4.5‐12.0).ConclusionsTo the best of our knowledge, this is the largest retrospective study of patients with SS and MRCL. It provides an analysis of real‐world clinical outcomes among patients treated at major sarcoma cancer centers and could inform treatment decisions and design of clinical trials. In general, the survival outcomes for this selected population appear more favorable than in published literature.
Highlights
Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are the two most common translocation-driven soft tissue sarcoma subtypes and share a number of important clinical and biologic features.[1]
In clinical trial data sets specific to synovial sarcoma (SS) and/or MRCL, the quality of data is limited by the heterogeneity of patients, sparse staging information, and varying length of survival follow-up, which limits the generalizability of results.[3,4,5,6,7,8,10,20,21]
Data were abstracted from medical records of 350 patients diagnosed with either SS or MRCL and treated for locally advanced/unresectable or metastatic disease at nine United States cancer centers that specialize in management of soft tissue sarcoma
Summary
Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are the two most common translocation-driven soft tissue sarcoma subtypes and share a number of important clinical and biologic features.[1]. A review of the literature regarding SS and MRCL clinical outcomes identified only retrospective series and post hoc subgroup analyses from randomized clinical trials.[3,4,5,6,7,8,10,20,21] In SS and MRCL, there is an unmet need to better understand clinical outcomes to inform clinical management of these sarcomas and design prospective clinical studies.[3,7] In clinical trial data sets specific to SS and/or MRCL, the quality of data is limited by the heterogeneity of patients, sparse staging information, and varying length of survival follow-up, which limits the generalizability of results.[3,4,5,6,7,8,10,20,21] Recent studies have reported the need for improved understanding of the tumor biology, pattern of spread, prognostic factors, and treatments that lead to improved outcomes in SS and MRCL.[3,6,7] The objective of this multi-center, retrospective registry study was to document the clinical outcomes of patients with advanced SS or MRCL treated with at least 1 line of systemic anticancer therapy using data from real world experience. These data could inform the design of trials with novel agents in the future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
